Chan Christopher J, Andrews Daniel M, Smyth Mark J
Peter MacCallum Cancer Centre, East Melbourne, Australia.
Eur J Immunol. 2008 Nov;38(11):2964-8. doi: 10.1002/eji.200838764.
Our current knowledge of NK-cell recognition and effector function suggests that it will be possible to design various new NK-cell-based immunotherapies against human cancer. The application of NK cells is already showing promise using HLA-mismatched haematopoietic stem cell transplantation for treatment of haematological malignancies. A better understanding of NK-cell heterogeneity and function will only broaden the applications for human cancer. Here we review the key developments that will propel this field.
我们目前对自然杀伤(NK)细胞识别和效应功能的了解表明,设计各种新型的基于NK细胞的人类癌症免疫疗法是可行的。利用人类白细胞抗原(HLA)不匹配的造血干细胞移植治疗血液系统恶性肿瘤,NK细胞的应用已显示出前景。对NK细胞异质性和功能的更深入了解只会拓宽其在人类癌症治疗中的应用。在此,我们回顾将推动该领域发展的关键进展。